Core Insights - Alkami Technology, Inc. is under investigation for potential securities fraud and unlawful business practices [1] - The company reported third-quarter 2025 financial results, with GAAP earnings per share of -$0.14, missing estimates by $0.02, and revenue of $113 million, missing estimates by $0.48 million [2] - Following the earnings report, Alkami's stock price dropped by $1.70, or 7.73%, closing at $20.29 per share [2] Company Financial Performance - For Q3 2025, Alkami reported a GAAP earnings per share of -$0.14, which was below the consensus estimate by $0.02 [2] - The revenue for the same quarter was $113 million, falling short of consensus estimates by $0.48 million [2] Stock Market Reaction - The announcement of the financial results led to a decline in Alkami's stock price by $1.70, representing a 7.73% decrease [2]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Bitdeer Technologies Group regarding potential securities fraud or unlawful business practices [1] Financial Performance - Bitdeer reported unaudited financial results for Q3 2025, with earnings per share of -$1.28, significantly missing the consensus estimate of -$0.22 [2] - Following the earnings report, Bitdeer's stock price fell by $2.63 per share, or 14.9%, closing at $15.02 on November 11, 2025 [2] Operational Issues - Bitdeer disclosed a significant delay in the development of its next-generation Seal 04 ASIC chip [2] - A fire incident occurred at Bitdeer's under-construction facility in Massillon, Ohio, damaging 2 of the 26 buildings [2] - The stock price dropped further by $2.83 per share, or 20.3%, closing at $11.11 on November 13, 2025, following the fire incident [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Regencell Bioscience Holdings Limited and its officers or directors [1][2]. Group 1: Investigation Details - Regencell disclosed on October 31, 2025, that it received a subpoena from the U.S. Department of Justice (DOJ) regarding an investigation into trading of its Ordinary Shares [2]. - The DOJ has requested documents and communications related to corporate operational, financial, and accounting matters [2]. - Regencell anticipates incurring significant legal costs and may face fines or penalties exceeding its insurance coverage due to the investigation [2]. Group 2: Market Reaction - Following the announcement of the DOJ investigation, Regencell's stock price dropped by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025 [2].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud or unlawful business practices by Beyond Meat, Inc. and its officers or directors, following significant stock price declines related to impairment charges and delayed earnings announcements [1][2]. Group 1: Company Financial Issues - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, related to long-lived assets, which was anticipated to be material [2]. - Following this announcement, Beyond Meat's stock price dropped by $0.655 per share, or 23.06%, closing at $2.185 per share on the same day [2]. - On November 3, 2025, the company delayed its third-quarter earnings announcement, citing the need for additional time to complete the impairment review, resulting in a further stock price decline of $0.275 per share, or 16.52%, closing at $1.39 per share [2]. Group 2: Legal Investigation - Pomerantz LLP, a firm recognized for its work in corporate and securities class litigation, is leading the investigation into Beyond Meat's practices, emphasizing its long history of fighting for victims of securities fraud and corporate misconduct [3].

Core Insights - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Zimmer Biomet and its executives [1] - Zimmer Biomet reported third-quarter 2025 net sales of $2 billion, which fell short of the consensus estimate of $2.01 billion [2] - The company revised its full-year organic revenue growth outlook down to a range of 3.5% to 4%, from a previous range of 3.5% to 4.5% [2] - Weakness in international markets and non-core businesses, along with order cancellations in the Middle East and Eastern Europe, negatively impacted results [2] - The stock price of Zimmer Biomet dropped by $15.63 per share, or 15.5%, closing at $87.55 on November 5, 2025, following the earnings announcement [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Owens Corning and its officers/directors following a significant financial loss reported in Q3 2025 [1][2]. Financial Performance - Owens Corning reported a net loss of $495 million, or $5.93 per diluted share, for Q3 2025, a stark contrast to a net income of $287 million, or $3.26 per share, in the same period of 2024 [2]. - The loss was primarily attributed to a $780 million non-cash impairment charge related to the Company's doors business [2]. - The Company anticipates a decline in revenue for Q4 2025, projecting between $2.1 billion and $2.2 billion due to soft residential markets and reduced demand for storm-related roofing [2]. Market Reaction - Following the announcement of the financial results, Owens Corning's stock price fell by $11.69 per share, or 9.53%, closing at $111.03 per share on November 5, 2025 [2].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Savers Value Village, Inc. and its officers or directors [1]. Group 1: Company Overview - Savers Value Village, Inc. conducted its initial public offering (IPO) on June 29, 2023, offering 25,635,415 shares at a price of $18.00 per share [2]. - The company reported a non-GAAP profit of $0.14 per share for the third quarter of 2025, but a GAAP loss of $0.09 per share [2]. Group 2: Market Reaction - Following the financial results announcement, Savers' stock price dropped by $4.02, or 30.39%, closing at $9.21 per share on October 31, 2025 [2].

Core Insights - Varonis Systems, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results [1][2] Financial Performance - On October 28, 2025, Varonis reported third-quarter financial results that missed consensus estimates, including a significant 63.9% year-over-year decline in term license subscription revenues [2] - The company reduced its full-year Annual Recurring Revenue (ARR) guidance due to underperformance in its on-premises subscription business [2] - CEO Yakov Faitelson indicated that the on-premises subscription business is negatively impacting overall company ARR growth, citing lower renewal rates and sales process issues as contributing factors [2] Stock Market Reaction - Following the announcement of the financial results, Varonis's stock price dropped by $30.66 per share, or 48.67%, closing at $32.34 per share on October 29, 2025 [2]

Core Insights - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving VirTra, Inc. and its officers or directors [1] - VirTra reported third-quarter 2025 financial results, with GAAP earnings per share of -$0.03, missing consensus estimates by $0.07, and revenue of $5.3 million, missing consensus by $1.69 million [2] - Following the earnings report, VirTra's stock price decreased by $0.43, or 7.93%, closing at $4.99 per share on November 11, 2025 [2] Financial Performance - VirTra's GAAP earnings per share for Q3 2025 were -$0.03, which was below the consensus estimate by $0.07 [2] - The company's revenue for the same period was reported at $5.3 million, missing the consensus estimate by $1.69 million [2] - The CEO indicated that a slower federal funding cycle and the timing of federal awards impacted near-term revenue recognition [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Western Alliance Bancorporation and its officers or directors [1]. Group 1: Legal Actions and Stock Impact - On October 16, 2025, Western Alliance filed a lawsuit against Cantor Group V LLC, alleging fraud related to collateral loans [2]. - Following the lawsuit announcement, Western Alliance's stock price dropped by $8.52 per share, representing a decline of 10.81%, closing at $70.32 per share [2]. Group 2: Pomerantz LLP Overview - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in the field [3]. - The firm has successfully recovered numerous multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [3].